Dr. Campbell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6931 Arlington Rd
Bethesda, MD 20814Phone+1 301-907-2689- Is this information wrong?
Education & Training
- Vanderbilt University Medical CenterFellowship, Pediatric Pulmonology, 1990 - 1993
- Vanderbilt University Medical CenterResidency, Pediatrics, 1980 - 1983
- University of Virginia School of MedicineClass of 1980
Certifications & Licensure
- MD State Medical License 1998 - 2022
- TN State Medical License 1982 - 1999
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- 37 citationsMicrobiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trialMarianne S. Muhlebach, Valeria V. Beckett, Elena B. Popowitch, Melissa B. Miller, Arthur Baines, Nicole Mayer-Hamblett, Edith T. Zemanick, Wynton C. Hoover, Jill M. Va...> ;Thorax. 2017 Apr 1
- 107 citationsSweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial dataFrank J. Accurso, Fredrick Van Goor, Jiuhong Zha, Anne Stone, Qunming Dong, Claudia L. Ordoñez, Steven M. Rowe, John P. Clancy, Michael W. Konstan, Heather Hoch, Sonya...> ;Journal of Cystic Fibrosis. 2014 Mar 1
- 409 citationsResults of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationJohn P. Clancy, Steven M. Rowe, Frank J. Accurso, Moira L. Aitken, Raouf S. Amin, Melissa A. Ashlock, Manfred Ballmann, Michael P. Boyle, Inez Bronsveld, Preston W. Ca...> ;Thorax. 2012 Jan 1
- Join now to see all
Press Mentions
- New Drug Appears to Slow Effects of Cystic Fibrosis, Offering Hope to Long-Suffering PatientsDecember 18th, 2019
- Cystic Fibrosis Foundation Statement on FDA Approval of TRIKAFTA, the First Triple-Combination Therapy for the Most Common CF MutationNovember 7th, 2019
- Preston W. Campbell, President and CEO of the Cystic Fibrosis Foundation to Retire; Michael P. Boyle, MD, Appointed as Successor Effective January 2020May 21st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: